<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA</journal-id><journal-id journal-id-type="iso-abbrev">JAMA</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>JAMA</journal-title></journal-title-group><issn pub-type="ppub">0098-7484</issn><issn pub-type="epub">1538-3598</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5408574</article-id><article-id pub-id-type="pmcid-ver">PMC5408574.1</article-id><article-id pub-id-type="pmcaid">5408574</article-id><article-id pub-id-type="pmcaiid">5408574</article-id><article-id pub-id-type="manuscript-id">NIHMS858354</article-id><article-id pub-id-type="pmid">27022822</article-id><article-id pub-id-type="doi">10.1001/jama.2016.3775</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS858354</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA858354</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond One Year after Percutaneous Coronary Intervention: An Analysis from the Randomized Dual Antiplatelet Therapy Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Yeh</surname><given-names initials="RW">Robert W.</given-names></name><degrees>MD, MSc</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Secemsky</surname><given-names initials="EA">Eric A.</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kereiakes</surname><given-names initials="DJ">Dean J.</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Normand</surname><given-names initials="SLT">Sharon-Lise T.</given-names></name><degrees>PhD</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gershlick</surname><given-names initials="AH">Anthony H.</given-names></name><degrees>MBBS</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cohen</surname><given-names initials="DJ">David J.</given-names></name><degrees>MD, MSc</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Spertus</surname><given-names initials="JA">John A.</given-names></name><degrees>MD, MPH</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Steg</surname><given-names initials="PG">Philippe Gabriel</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cutlip</surname><given-names initials="DE">Donald E.</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rinaldi</surname><given-names initials="MJ">Michael J.</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Camenzind</surname><given-names initials="E">Edoardo</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wijns</surname><given-names initials="W">William</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Apruzzese</surname><given-names initials="PK">Patricia K.</given-names></name><degrees>MA</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Song</surname><given-names initials="Y">Yang</given-names></name><degrees>MS</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Massaro</surname><given-names initials="JM">Joseph M.</given-names></name><degrees>PhD</degrees></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mauri</surname><given-names initials="L">Laura</given-names></name><degrees>MD, MSc</degrees></contrib><on-behalf-of>on behalf of the DAPT Study Investigators</on-behalf-of><aff id="A1">The Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center (RWY), Cardiology Division, Massachusetts General Hospital (EAS); Harvard Medical School (RWY, EAS, S-LTN, DEC, LM); Harvard Clinical Research Institute (RWY, EAS, DEC, PKA, YS, JMM, LM) - all in Boston, Massachusetts, USA; The Christ Hospital Heart and Vascular Center and The Lindner Center for Research and Education, Cincinnati, Ohio, USA (DJK); Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA (S-LTN); Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Cardiovascular Biomedical Research Unit, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK (AHG); Saint Luke&#8217;s Mid America Heart Institute, Kansas City, Missouri, USA (DJC, JAS);University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA (DJC, JAS); Washington University in Saint Louis, School of Medicine, St. Louis, Missouri, USA (JAS); Universit&#233; Paris-Diderot, INSERM U-1148, H&#244;pital Bichat, D&#233;partement Hospitalo-Universitaire Fibrosis, Inflammation, and Remodeling, Assistance Publique&#8211;H&#244;pitaux de Paris &#8211; all in Paris, France, National Heart and Lung Institute, Institute of Cardiovascular Medicine and Science, Royal Brompton Hospital, Imperial College, London, UK (PGS); Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA (DEC); The Sanger Heart and Vascular Institute, Carolinas HealthCare System, Charlotte, North Carolina, USA (MJR); Institut Loraine du Coeur et des Vaisseaux, University Hospital of Nancy-Brabois, Vandoeuvre-les-Nancy, France (EC); Cardiovascular Center, OLV Hospital, Aalst, Belgium (WW); Boston University School of Public Health, Boston, Massachusetts, USA (JMM), Brigham and Women&#8217;s Hospital (LM)</aff></contrib-group><author-notes><corresp id="FN1">Co-Corresponding Authors: Robert W. Yeh, MD, MSc, The Smith Center for Outcomes Research in Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, 185 Pilgrim Road, Telephone: 617.632.7393, Fax: 617.632.7620, <email>ryeh@bidmc.harvard.edu</email>. Laura Mauri, MD MSc, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women&#8217;s Hospital, 75 Francis Street, Boston, MA 02115, Telephone: 617.525.7605, <email>lmauri1@partners.org</email></corresp><fn fn-type="COI-statement" id="FN4"><p><bold><underline>Declaration of Interests</underline></bold></p><p><bold>Dr. Yeh</bold> reports personal fees from Abbott Vascular, Boston Scientific, and Merck, and research salary from Harvard Clinical Research Institute, outside the submitted work.</p><p><bold>Dr. Secemsky</bold> has nothing to disclose.</p><p><bold>Dr. Kereiakes</bold> has nothing to disclose.</p><p><bold>Dr. Normand</bold> has nothing to disclose</p><p><bold>Dr. Gershlick</bold> has nothing to disclose.</p><p><bold>Dr. Cohen</bold> reports grants and personal fees from Abbott Vascular, Medtronic, Astra-Zeneca, and Eli Lilly, and grants from Daichii-Sankyo, outside the submitted work.</p><p><bold>Dr. Spertus</bold> reports ownership of equity interest in Health Outcomes Sciences.</p><p><bold>Dr. Steg</bold> reports personal fees from Amarin, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers-Squibb, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck-Sharpe-Dohme, Novartis, CSL-Behring, Regeneron, Janssen, Pfizer, Regado, and Roche; grants and personal fees from Sanofi and Servier; and personal fees and non-financial support from The Medicines Company; outside the submitted work.</p><p><bold>Dr. Cutlip</bold> reports grants from Medtronic and Boston Scientific, outside the submitted work.</p><p><bold>Dr. Rinaldi</bold> reports serving on the advisory boards of Abbott Vascular and Boston Scientific.</p><p><bold>Dr. Camenzind</bold> has nothing to disclose.</p><p><bold>Dr. Wijns</bold> reports grants from Medtronic, during the conduct of the study; grants from Medtronic, Boston Scientific, Terumo, MiCell, Stentys, and Abbott Vascular, outside the submitted work; and non-executive Board member and shareholder of Argonauts Partners, Celyad and Genae Inc.</p><p><bold>Ms. Apruzzese</bold> has nothing to disclose.</p><p><bold>Mr. Song</bold> has nothing to disclose.</p><p><bold>Dr. Massaro</bold> reports personal fees from Harvard Clinical Research Institute during the conduct of the study.</p><p><bold>Dr. Mauri</bold> reports grants from Abbott, Boston Scientific, Cordis, Bristol-Myers Squibb, and Daiichi Sankyo; grants and personal fees from Medtronic, Eli Lilly and Company, Sanofi, Boehringer Ingelheim, Biotronik; personal fees from Amgen, Recor, Astra Zeneca, and St. Jude, outside the submitted work</p></fn></author-notes><pub-date pub-type="ppub"><day>26</day><month>4</month><year>2016</year></pub-date><volume>315</volume><issue>16</issue><issue-id pub-id-type="pmc-issue-id">291562</issue-id><fpage>1735</fpage><lpage>1749</lpage><pub-history><event event-type="nihms-submitted"><date><day>31</day><month>03</month><year>2017</year></date></event><event event-type="pmc-release"><date><day>28</day><month>04</month><year>2017</year></date></event><event event-type="pmc-live"><date><day>28</day><month>04</month><year>2017</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-17 14:25:12.653"><day>17</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms858354.pdf"/><abstract><sec id="S1"><title>Importance</title><p id="P1">Dual antiplatelet therapy after percutaneous coronary intervention (PCI) reduces ischemia at the expense of increased bleeding.</p></sec><sec id="S2"><title>Objective</title><p id="P2">To develop a clinical decision tool to identify patients expected to derive benefit vs. harm from continuing thienopyridine beyond one year after PCI.</p></sec><sec id="S3"><title>Design/Setting</title><p id="P3">From DAPT Study data, a prediction rule was derived stratifying patients into groups to distinguish ischemic and bleeding risk 12&#8211;30 months after PCI. Validation was internal via bootstrap resampling and external within the Patient Related OuTcomes with Endeavor versus Cypher stenting (PROTECT) trial.</p></sec><sec id="S4"><title>Participants</title><p id="P4">Derivation group: 11,648 randomized DAPT Study patients from 11 countries (August 2009&#8211;May 2014). Validation group: 8,709 randomized PROTECT trial patients from 36 countries (June 2007&#8211;July 2014).</p></sec><sec id="S5"><title>Exposure</title><p id="P5">12 months open-label thienopyridine plus aspirin; 18 months randomized continued thienopyridine plus aspirin vs. placebo plus aspirin.</p></sec><sec id="S6"><title>Main Outcome Measure</title><p id="P6">Ischemia (stent thrombosis or myocardial infarction [MI]) and bleeding (GUSTO moderate/severe) 12&#8211;30 months after PCI.</p></sec><sec id="S7"><title>Results</title><p id="P7">Among the derivation population (mean age 61.3 years, 25.2% female), ischemia occurred in 348 (3.0%) and bleeding in 215 (1.8%). Derivation cohort models predicting ischemia and bleeding had c-statistics of 0.70 and 0.68, respectively. The prediction rule assigned 1 point each for MI at presentation, prior MI or PCI, diabetes, stent diameter &lt;3 mm, smoking, and paclitaxel-eluting stent; 2 points each for history of congestive heart failure/low ejection fraction and vein graft intervention; &#8722;1 point for age 65&#8211;&lt;75; and &#8722;2 points for age &#8805; 75. For patients with high scores (&#8805; 2, n=5917), continued thienopyridine (vs. placebo) was associated with reduced ischemic events (2.7% vs. 5.7%, risk difference [RD] &#8722;3.0%, 95% CI &#8722;4.1% to &#8722;2.0%, p&lt;0.001), compared to those with low scores (&lt;2, n=5731, 1.7% vs. 2.3%, RD &#8722;0.7%, 95% CI &#8722;1.4% to 0.09%, p=0.07, interaction p&lt; 0.001). Conversely, continued thienopyridine was associated with smaller increases in bleeding among scores &#8805;2 (1.8% vs. 1.4%, RD 0.4%, 95% CI &#8722;0.3% to 1.0%, p=0.26) compared with low scores &lt;2 (3.0% vs. 1.4%, RD 1.5%, 95% CI 0.8% to 2.3%, p&lt;0.001; interaction p=0.02). Mortality rates were 2.1% for continued thienopyridine vs. 2.1% for placebo (p=0.99) for scores &#8805;2, compared to 1.7% vs. 0.9%, respectively (p=0.02, interaction p=0.14 &#8211; non-significant) for scores &lt;2. Among the validation cohort (mean age 62 years; 2,061 (23.7%) women), ischemia occurred in 365 (4.2%) and bleeding in 171 (2.0%), with c statistic 0.64 for ischemia model and 0.64 for bleeding. In this cohort, high score patients had increased ischemic events (1.5% vs. 0.7%, RD 0.73%, 95% CI 0.23% to 1.23%, p=0.002), and no significant difference in bleeding (0.4% vs. 0.5%, RD &#8722;0.16%, 95% CI &#8722;0.46% to 0.13%, p=0.31).</p></sec><sec id="S8"><title>Conclusion and Relevance</title><p id="P8">Among patients not sustaining major bleeding or ischemic events one year after PCI, a prediction rule assessing ischemic and bleeding risks showed modest accuracy in derivation and validation cohorts. This rule requires further prospective evaluation to assess potential effects on patient care, as well as validation in other cohorts.</p></sec><sec id="S9"><title>Trial Registration</title><p id="P9">ClinicalTrials.gov number <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00977938">NCT00977938</ext-link>.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>